Micrornas in prostate cancer: An overview

Oncotarget

Volumn 8, Issue 30, 2017, Pages 50240-50251

  Vanacore, Daniela ^a,b   Boccellino, Mariarosaria ^b   Rossetti, Sabrina ^a,c   Cavaliere, Carla ^a,d   D'Aniello, Carmine ^a,e   Di Franco, Rossella ^a,c   Romano, Francesco Jacopo ^a   Montanari, Micaela ^a,f   La Mantia, Elvira ^a,c   Piscitelli, Raffaele ^a,c   Nocerino, Flavia ^a,c   Cappuccio, Francesca ^a,c   Grimaldi, Giovanni ^a,c   Izzo, Alessandro ^a,c   Castaldo, Luigi ^a,c   Pepe, Maria Filomena ^a,c   Malzone, Maria Gabriella ^a,c   Iovane, Gelsomina ^c   Ametrano, Gianluca ^a,c   Stiuso, Paola ^b   Quagliuolo, Lucio ^b   Barberio, Daniela ^a,c   Perdonà, Sisto ^c   Muto, Paolo ^c   Montella, Maurizio ^c   Maiolino, Piera ^c   Veneziani, Bianca Maria ^f   Botti, Gerardo ^c   Caraglia, Michele ^b   Facchini, Gaetano ^a,c   more..

^a Regione Campania   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e MONALDI HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biomarkers; MicroRNAs; Oncogenic miRNAs; Prostate cancer; Tumor suppressor miRNAs

Indexed keywords

LET 7 MICRORNA; MICRORNA; MICRORNA 133; MICRORNA 135A 1; MICRORNA 145; MICRORNA 146A; MICRORNA 17 92A; MICRORNA 200B; MICRORNA 204 5P; MICRORNA 224; MICRORNA 27A; MICRORNA 30A; MICRORNA 34A; MICRORNA 372; MICRORNA 382; MICRORNA 452; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN RNA BINDING; REVIEW; RNA PROCESSING; RNA SYNTHESIS; GENETICS; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

BIOMARKERS, TUMOR; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS;

EID: 85025823355     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16933     Document Type: Review

References (117)

1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003; 361:859-64.
2. Caraglia M, Alaia C, Grimaldi A, Boccellino M, Quagliuolo L. MiRNA as prognostic and therapeutic targets in tumor of male urogenital tract. Mol Targets Strat Cancer Prev. 2016; 7:151-171.
3. Fong MK, Hare R, Jarkowski A. A new era for castrate resistant prostate cancer: a treatment review and update. J Oncol Pharm Pract. 2012; 18:343-354.
4. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol. 2013; 232:178-184.
5. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients. Phase I ZANTE Trial. Cancer Biol Ther. 2010; 10:543-8.
6. Marra M, Santini D, Tonini G, Meo G, Zappavigna S, Facchini G, Morabito A, Abbruzzese A, Cartenì G, Budillon A, Caraglia M. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. Eur J Cancer. 2008; 6:79-85.
7. Caraglia M, Giuberti G, Marra M, Di Gennaro E, Facchini G, Caponigro F, Iaffaioli RV, Budillon A, Abruzzese A. Docetaxel induces P53-dependent apoptosis and synergizes with farnesyl transefrase inhibitor R115777 in human epithelial cancer cells. Front Biosci. 2005; 2566-2575.
8. Frasci G, Iaffaioli RV, Perone V, Facchini G, De Rosa G, Bianco AR. Prostatic cancer with cutaneous involvement treated with Goserelin. Curr Ther Res. 1991; 49:169-73.
9. Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, Re GL, Amadio P, Bortolus R, Pagliarulo V, Prati V, Veccia A, Galligioni E. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol. 2012; 107:191-6.
10. Massimiliano Berretta, Chiara Della Pepa, Paolo Tralongo, Alberto Fulvi, Ferdinando Martellotta, Arben Lleshi, Guglielmo Nasti, Rossella Fisichella, Carmela Romano, Chiara De Divitiis, Rosaria Taibi, Francesco Fiorica, Raffaele Di Francia, et al. Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. Oncotarget. 2016; 8:24401-24414. doi: 10.18632/oncotarget.14224.
11. Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, et al. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology. 2016; 12:493-502.
12. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol. 2015; 68:147-153.
13. Della Pepa C, D'Aniello C, Rossetti S, Iovane G, Pisconti S, Fisichella R, Facchini G, Cavaliere C. "Reallife" effectiveness studies in mCRPC patients: systematic review. WCRJ. 2015; 2:e617.
14. Della Pepa C, Cavaliere C, Rossetti S, Di Napoli M, Cecere SC, Crispo A, De Sangro C, Rossi E, Turitto D, Germano D, Iovane G, Berretta M, D'Aniello C, et al. Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results. Anticancer Drugs. 2017; 28:104-109.
15. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol. 2005; 23:8232-8241.
16. Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F, Rossetti S, D'Aniello C, Cavaliere C, Romano FJ, Malzone MG, Montanari M, Vanacore D, et al. Hypofractionated versus conventional radiotherapy in patients with low/intermediate-risk localized prostate cancer: review of rectal and urinary toxicity. WCRJ. 2016; 3: e751.
17. D'Aniello C, Cavaliere C, Fiorica F, Facchini G. Letter to the Editor-Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016; 20:4626-4627.
18. Valerio Nardone, Cirino Botta, Michele Caraglia, Elodia Claudia Martino, Maria Raffaella Ambrosio, Tommaso Carfagno, Paolo Tini, Leonardo Semeraro, Gabriella Misso, Anna Grimaldi, Mariarosaria Boccellino, Gaetano Facchini, Massimiliano Berretta, et al. "Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse". Cancer Biol Ther. 2016; 17:1213-1220.
19. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011; 59:61-71.
20. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007; 249:30-9.
21. Boccellino M, Alaia C, Misso G, Cossu AM, Facchini G, Piscitelli R, Quagliuolo L, Caraglia M. Gene interference strategies as a new tool for the treatment of prostate cancer. Endocrine. 2015; 49:588-605.
22. Gaetano Facchini, Orazio Caffo, Cinzia Ortega, Carmine D'Aniello, Marilena Di Napoli, Sabrina Chiara Cecere, Chiara Della Pepa, Anna Crispo, Francesca Maines, Fiorella Ruatta, Gelsomina Iovane, Salvatore Pisconti, Maurizio Montella, et al. Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival. Front Pharmacol. 2016; 123.
23. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012; 10:106-13.
24. Cristian Lolli, Orazio Caffo, Emanuela Scarpi, Michele Aieta, Vincenza Conteduca, Francesca Maines, Emanuela Bianchi, Francesco Massari, Antonello Veccia, Vincenzo E Chiuri, Gaetano Facchini, Ugo De Giorgi. "Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone". Front Pharmacol. 2016; 7:376.
25. Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, et al. Predictors of longterm response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget. 2016; 7:40085-40094. doi: 10.18632/oncotarget.9485.
26. Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, et al. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol. 2015; 11:965-973.
27. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320-8.
28. Epstein JI. An update of the Gleason grading system. J Urol. 2010; 183:433-440.
29. Mellinger GT, Gleason D, Bailar J 3rd. The histology and prognosis of prostatic cancer. J Urol. 1967; 97:331-337.
30. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24:1967-2000.
31. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24:1967-2000.
32. Squire JA, Park PC, Yoshimoto M, Alami J, Williams JL, Evans A, Joshua AM. Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res. 2011; 112:183-216.
33. Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013; 19:4058-4066.
34. De Cobelli O, Buonerba C, Terracciano D, Danilo B, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, et al. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol. 2015; 11:3091-8.
35. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. 2015; 33:85-94.
36. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-97.
37. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol Cell. 2007; 28:328-336.
38. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell. 2007; 130:89-100.
39. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature. 2007; 448:83-86.
40. Xie M, Li M, Vilborg A, Lee N, Shu MD, Yartseva V, Šestan N, Steitz JA. Mammalian 5'-capped microRNA precursors that generate a single microRNA. Cell. 2013; 155:1568-1580.
41. CheloufiS, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010; 465:584-589.
42. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, CheloufiS, Ma E, Mane S, Hannon GJ, Lawson ND, Wolfe SA, Giraldez AJ. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010; 328:1694-1698.
43. Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R, Papapetrou EP, Sadelain M, O'Carroll D, Lai EC. Conserved vertebrate mir-451 provides a platform for Dicerindependent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci USA. 2010; 107:15163-15168.
44. Yoda M, Cifuentes D, Izumi N, Sakaguchi Y, Suzuki T, Giraldez AJ, Tomari Y. Poly(A)-specific ribonuclease mediates 3'-end trimming of Argonaute2-cleaved precursor microRNAs. Cell Rep. 2013; 5:715-726.
45. Watanabe Y, Tomita M, Kanai A. Computational methods for microRNA target prediction. Methods Enzymol. 2007; 427:65-86.
46. Saito T, Saetrom P. MicroRNAs-targeting and target prediction. N Biotechnol. 2010; 27:243-249.
47. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27:91-105.
48. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high targetsite abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011; 18:1139-1146.
49. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19:92-105.
50. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120:15-20.
51. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012; 6:590-610.
52. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015;17;8:re3.
53. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010; 1803:1231-1243.
54. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011; 18:1111-1120.
55. Price C, Chen J. MicroRNAs in cancer biology and therapy: Current status and perspectives. Genes Dis. 2014; 1:53-63.
56. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20:460-469.
57. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9:775-789.
58. Hutzvanger G, Simard MJ, Mello CC, Zamore PD. Sequence specific inhibition of small RNA function. Plos Biol. 2004; 2:E98.
59. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs); amunition to target miRNAs implicated in human disease? Gene Therapy. 2006; 13:496-502.
60. Vester B, Wengel J. LNA (locked nucleic acid): high affinity targeting of complementary RNA and DNA. Biochemistry. 2004; 43:13233-13241.
61. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specific interference via manipulating actions of micro-RNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol. 2007; 212:285-92.
62. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science. 2007; 318:271-4.
63. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008; 47:7482-4.
64. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet. 2009; 67:29-60.
65. Aagaard L, Rossi JJ. RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliver Rev. 2007; 59:75-86.
66. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259-269.
67. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006; 25 :2537-45.
68. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. PNAS USA. 2005; 102:19075-80.
69. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9:189-98.
70. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, et al. 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006; 103:2257-61.
71. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther. 2011; 11:859-69.
72. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
73. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8:467-477.
74. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, Dahlsveen IK. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013; 59:S1-S6.
75. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012; 13:358-369.
76. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-838.
77. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM, Shen ZJ. miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer. J Urol. 2012; 187:1466-1472.
78. Cannistraci A, Di Pace AL, De Maria R, Bonci D. MicroRNA as new tools for prostate cancer risk. Assessment and therapeutic intervention: results from clinical data set and patients' samples. Biomed Res Int. 2014; 146170. doi: 10.1155/2014/146170.
79. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafrè SA. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PloS One. 2008; 3:e4029. doi:10.1371/journal. pone.0004029.
80. Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26:3699-708.
81. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG. miR-221 andmiR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007; 282:23716-24.
82. Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, Dai B, Ye DW. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl. 2013; 15:231-5.
83. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105:10513-8.
84. Wen J, Li R, Wen X, Chou G, Lu J, Wang X, Jin Y. Dysregulation of cell cycle related genes and microRNAs distinguish the low-from high-risk of prostate cancer. Diagn Pathol. 2014; 9:156. doi: 10.1186/s13000-014-0156-1.
85. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Brit J Cancer. 2012; 106:768-774.
86. Al-Kafaji G, Al-Naieb ZT, Bakhiet M. Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker. Oncol Lett. 2016; 11:1201-1206.
87. Rea D, Del Vecchio V, Palma G, Barbieri A, Falco M, Luciano A, De Biase D, Perdonà S, Facchini G, Arra C. Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. Biomed Res Int. 2016.
88. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016; 7:68371-68384. doi: 10.18632/oncotarget.12031.
89. Zuo ZH, Yu YP, Ding Y, Liu S, Martin A, Tseng G, Luo JH. Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression. Am J Pathol. 2015; 185:1991-9.
90. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, TammelaTL, Visakorpi T. Androgenregulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012; 31:4460-71.
91. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013; 4:350-7.
92. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PloS One. 2013; 8:e61064.
93. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor suppressor genes. Curr Biol. 2007; 17:1298-1307.
94. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447:1130-4.
95. Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, et al. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget. 2016; 7:85641-85649. doi: 10.18632/oncotarget.13063.
96. ChieffiP, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int. Rev Cell Mol Biol 2009; 278: 277-308.
97. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26:745-52.
98. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26:731-743.
99. Tazawa H, Tsuchiya N, Izumiya M & Nakagama H. Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. PNAS. 2007; 104:15472-15477.
100. Sachdeva M, Zhu SM, Wu FT, Wu HL, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. PNAS USA. 2009; 106:3207-3212.
101. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65:7065-7070.
102. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007; 72:397-402.
103. Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Brit J Cancer. 2013; 108:2573-2581.
104. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013; 1:3-9.
105. Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, Ozen M. miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer. PLoS One. 2014; 9:e98675.
106. Zhang Z, Lanz RB, Xiao L, Wang L, Hartig SM, Ittmann MM, Feng Q, He B. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget. 2016; 7:37993-38003. doi: 10.18632/oncotarget.9366.
107. Zhang W, Liu J, Qiu J, Fu X, Tang Q, Yang F, Zhao Z, Wang H. MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII. Oncol Rep. 2016; 36:3707-3715.
108. Kong X, Qian X, Duan L, Liu H, Zhu Y, Qi J. microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells. DNA Cell Biol. 2016; 35:828-835.
109. Ottman R, Levy J, Grizzle WE, Chakrabarti R. The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer. Oncotarget. 2016; 7:73739-73753 doi:10.18632/oncotarget.12061.
110. Wan X, Huang W, Yang S, Zhang Y, Zhang P, Kong Z, Li T, Wu H, Jing F, Li Y. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. Int J Biochem Cell Biol. 2016; 79:249-260.
111. Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen S, Zhu W, Chen M. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR. Tumor Biol. 2016; 37:14141-14151.
112. Lin YC, Lin JF, Tsai TF, Chou KY, Chen HE, Hwang TI. Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells. Asian J Surg. 2016; 9 pii:S1015-958430173-7.
113. Zhang L, Zhang XW, Liu CH, Lu K, Huang YQ, Wang YD, Xing L, Zhang LJ, Liu N, Jiang H, Sun C, Yang Y, Chen SQ, et al. miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer. Mol Med Rep. 2016; 14:2077-84.
114. Esposito F, Libertini S, Franco R, Abagnale A, Marra L, Portella G, ChieffiP. Aurora B expression in post-puberal testicular germ cell tumours. J Cell Physiol. 2009; 221:435-9.
115. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, et al. Loss of let-7 upregulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PloS One. 2012; 7:e33729.
116. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C. Epidermal growth factor receptor activation in androgen-independent but not androgenstimulated growth of human prostatic carcinoma cells. Br J Cancer. 1998; 77:855-61.
117. Vitale G, Dicitore A, Messina E, Sciammarella C, Faggiano A, Colao A. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy. Recent Pat Anticancer Drug Discov. 2016; 11:275-82.